Show simple item record

dc.contributor.authorDe la Cruz-Merino, Luis
dc.contributor.authorGrande-Pulido, E.
dc.contributor.authorAlbero-Tamarit, Ana
dc.contributor.authorCodes-Manuel de Villena, Manuel Eduardo
dc.date.accessioned2024-01-23T12:03:24Z
dc.date.available2024-01-23T12:03:24Z
dc.date.issued2008
dc.identifier.issn1549-490Xspa
dc.identifier.urihttps://hdl.handle.net/10641/3802
dc.description.abstractCancer may occur as a result of abnormal host immune system tolerance. Recent studies have confirmed the occurrence of spontaneous and induced antitumor immune responses expressed as the presence of tumor-infiltrating T cells in the tumor microenvironment in some cancer models. This finding has been recognized as a good prognostic factor in several types of tumors. Some chemotherapy agents, such as anthracyclines and gemcitabine, are effective boosters of the immune response through tumor-specific antigen overexpression after apoptotic tumor cell destruction. Other strategies, such as GM-CSF or interleukin-2, are pursued to increase immune cell availability in the tumor vicinity, and thus improve both antigen presentation and T-cell activation and proliferation. In addition, cytotoxic T lymphocyte antigen 4 – blocking monoclonal antibodies enhance immune activity by prolonging T-cell activation. Strategies to stimulate the dormant immune system against tumors are varied and warrant further investigation of their applications to cancer therapy in the future.spa
dc.language.isoengspa
dc.publisherThe Oncologistspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectCancerspa
dc.subjectTumor-infiltrating lymphocytesspa
dc.subjectImmune tolerancespa
dc.subjectCancer vaccinesspa
dc.subjectCTLA-4spa
dc.subjectGM-CSFspa
dc.subjectIL-2spa
dc.titleCancer and Immune Response: Old and New Evidence for Future Challenges.spa
dc.typejournal articlespa
dc.type.hasVersionSMURspa
dc.rights.accessRightsmetadata only accessspa
dc.description.extent751 KBspa
dc.identifier.doi10.1634/theoncologist.2008-0166spa
dc.relation.publisherversionhttps://academic.oup.com/oncolo/article/13/12/1246/6397403?login=falsespa


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España